Trial reportJournal of neuroimmunology2007
Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response.
Trial report in Journal of neuroimmunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Type I interferons for induction of remission in ulcerative colitis.The Cochrane database of systematic reviews · 2015Pooled it
- Cerebrospinal fluid inflammatory biomarkers predicting interferon-beta response in MS patients.Therapeutic advances in neurological disorders · 2020Article
- Tumor necrosis factor alpha (TNF-α) and its soluble receptors are associated with disability, disability progression and clinical forms of multiple sclerosis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019Article
- Disability in multiple sclerosis is associated with age and inflammatory, metabolic and oxidative/nitrosative stress biomarkers: results of multivariate and machine learning procedures.Metabolic brain disease · 2019Article
- Anti-inflammatory and cognitive effects of interferon-β1a (IFNβ1a) in a rat model of Alzheimer's disease.Journal of neuroinflammation · 2019Article
- Effects of IFN-β1a and IFN-β1b treatment on the expression of cytokines, inducible NOS (NOS type II), and myelin proteins in animal model of multiple sclerosis.Archivum immunologiae et therapiae experimentalis · 2017Article
- Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability.Molecular neurobiology · 2017Article
- Genetic, Immune-Inflammatory, and Oxidative Stress Biomarkers as Predictors for Disability and Disease Progression in Multiple Sclerosis.Molecular neurobiology · 2017Article
- Immune-mediated processes in neurodegeneration: where do we stand?Journal of neurology · 2016Review
- Cytokine Therapies in Neurological Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2016Review
- Article
- Biomarker studies in multiple sclerosis: from proteins to noncoding RNAs.Neurochemical research · 2014Review
- Immunomodulatory activity of interferon-beta.Annals of clinical and translational neurology · 2014Review
- Interleukin 18 gene polymorphism is a risk factor for multiple sclerosis.Molecular biology reports · 2014Article
- Activated human CD4+CD45RO+ memory T-cells indirectly inhibit NLRP3 inflammasome activation through downregulation of P2X7R signalling.PloS one · 2012Article
- Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis.PloS one · 2011Article
- T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.Nature medicine · 2010Article
- Early stage and long term treatment of multiple sclerosis with interferon-beta.Biologics : targets & therapy · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
We investigated serum (IL-10 and IL-12p70) and cellular cytokine levels (IL-10, IL-12p40, IL-12p70, IFN-gamma) in stimulated PBMC over 24 weeks in 15 relapsing-remitting multiple sclerosis (MS) patients randomized to receive once-weekly (qw) IFN-beta-1a 30 microg intramuscularly (IM) (n=8) or three-times-weekly (tiw) IFN-beta-1a 44 microg subcutaneously (SC) (n=7). Overall, IFN-beta treatment increased cellular IL-10 (p<0.01) levels and the ratios of cellular IL-10/IL-12p40 (p<0.01) and IL-10/IL-12p70 (p<0.02) while cellular IFN-gamma levels were reduced (p<0.01). Serum IL-10 levels were decreased in non-responders to therapy based on MRI-defined criteria (p<0.01) but did not change in responders over the course of treatment. In addition, non-responders demonstrated a decrease in serum IL-10/IL-12p70 ratio (p=0.031) and a decrease in cellular IL-12p70 (p<0.02). A decrease in cellular IFN-gamma was observed in responders (p=0.013). This is the first study that compares cytokine changes between the two IFN-beta regimes and demonstrates that serum IL-10 levels decrease in those patients who continue to have active MRI lesions while on interferon-beta therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.